Clinical Trial Update: A Single-arm Phase II Study of Alemtuzumab in Combination With High-dose Methylprednisolone in CLL Patients With p53 Deletion [Phase 2]

View source ↗

Summary

This report summarizes the completion of a single-arm Phase II study evaluating alemtuzumab in combination with high-dose methylprednisolone in chronic lymphocy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Alemtuzumab (Alemtuzumab)
• METHYLPREDNISOLONE (methylprednisolone)

Snippet

Sponsor: Royal Marsden NHS Foundation Trust | Conditions: Chronic Lymphocytic Leukaemia | Phase 2 | Status: COMPLETED